PIONEER: First Phase 3 Data on Oral Semaglutide in Diabetes PIONEER: First Phase 3 Data on Oral Semaglutide in Diabetes

Semaglutide, the first oral GLP-1 receptor agonist, shows HbA1c lowering and weight loss comparable to injectable version in type 2 diabetes; best efficacy confined to highest dose.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news